Navigation Links
Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
Date:4/17/2013

ase, acute limb ischemia, and blood transfusions, as well as the timing of activities related to those plans, and prospects for MST-188's clinical, regulatory and commercial success.  Among the factors that could cause or contribute to material differences between the Company's actual results and expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future nonclinical and clinical studies despite positive results in nonclinical testing and prior clinical studies; the potential for significant delays in the development of MST-188, including due to lack of funding, delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, completing necessary manufacturing process development activities, and being subject to a "clinical hold," or suspension or termination of a clinical study, including due to patient safety concerns; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of MST-188 in any particular indication in which the Company determines to develop MST-188, including acute limb ischemia, which likely would increase the total time and cost of development in the indication; the risk that clinical studies of MST-188 are not successfully executed and/or do not successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the risk that even if clinical studies of MST-188 in one indication or jurisdiction are successful,
'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
2. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
3. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
4. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
5. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
6. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
7. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
8. Halozyme Therapeutics Names Matt Posard to Board of Directors
9. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
10. Cell Therapeutics Secures $15 Million Loan Financing Agreement
11. United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014  Patients in today,s changing health care landscape ... an outpatient setting versus a hospital. In an effort ... that patients continue to receive high quality medical care; ... new internal medicine residency program. The program,s progressive curriculum ... clinic and even virtual settings. "We ...
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... owned subsidiary, Valeant Pharmaceuticals International, will redeem all of ... 6.75% Senior Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 ... has mailed an irrevocable notice of redemption for the ... of the irrevocable notice of redemption with respect to ...
Breaking Medicine Technology:Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2
... AARP Illinois Disappointed By Senate Vote Against Lower Prescription Drug ... on Tuesday night rejected an amendment to the Patient Protection ... more affordable by allowing for the safe and legal importation ... endorsed by AARP and sponsored by Senators Dorgan, Snowe, McCain, ...
... , SALT LAKE CITY, Dec. 16 ... or the "Company"), a medical device company engaged in the ... announced today that Joe Pepper, PhD, has been appointed to ... Hungerford commented, "Joe has extensive experience running small to large ...
Cached Medicine Technology:AARP Illinois Key Vote News Alert 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3
(Date:9/15/2014)... York, New York (PRWEB) September 15, 2014 ... C.R. Bard, Inc. continue to move forward in the ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... issued a Final Order on September 10th that provides ... The Order notes that none of the affected plaintiffs ...
(Date:9/15/2014)... studies, approximately one out of every 40 individuals in the ... spinal muscular atrophy (SMA), a neurodegenerative disease that causes muscles ... Missouri have made a recent breakthrough with the development of ... models of the disease. In April, a patent was filed ... our lab is using to fight SMA is to ,repress ...
(Date:9/15/2014)... 2014 This year, Avenidas Village ... 2007. To mark the special occasion, Avenidas Village would ... village and helping it to get started seven years ... fun community for seniors. Members of Avenidas Village maintain ... in their own homes. They are able to have ...
(Date:9/15/2014)... Sept. 15, 2014 (HealthDay News) -- Births of multiple ... and death than singleton births, researchers report. The ... in vitro fertilization (IVF) could ease some of that ... have increased in tandem with births to older mothers ... from the University of New South Wales, Australia. ...
(Date:9/15/2014)... 2014 Providing additional expertise to ... LLP (“the Firm”) is proud to welcome ... with the Firm’s Litigation Support Services ... experience, Wolf will assist clients in litigation support, ... advisory matters. He will also provide guidance in ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 2Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 3
... , NEW YORK, Nov. 18 WAT,s-THE-WORD?! is the first ... products, discoveries on the web and real-life experiences from a ... boys who helped their parents conceive the brand WAT-AAH! ... mom a "cooler" and better name for water, thus WAT-AAH!. ...
... 18 Banfield, The Pet Hospital® today announced ... its medical specialist/nutritionist. With nearly 20 years experience in veterinary ... platform that will position Banfield as a leader in veterinary ... as part of the Medical Quality Advancement team at Banfield,s ...
... , WASHINGTON, Nov. 18 The Union Labor ... subsidiary of ULLICO Inc., a privately held financial and ... provide pharmacy benefit management services to labor group clients. ... union employers and their members with a comprehensive pharmacy ...
... Institutet have discovered that patients with recent-onset schizophrenia have ... findings offer hope of being able to treat schizophrenia ... The causes of schizophrenia are largely unknown, and this ... that infections caught early on in life might increase ...
... have shown that lipid peroxidation stimulates collagen production ... plays an important role in the development of ... carbon tetrachloride, cholestasis and alcohol induced liver fibrosis ... effect of green tea in dimethylnitrosamine (DMN)-induced models ...
... stall carotid artery disease , WEDNESDAY, Nov. 18 (HealthDay ... additional benefit to seniors with coronary artery disease who ... , The 18-month study of 145 Baltimore-area men and ... arterial wall thickness reductions between those who took 1,500 ...
Cached Medicine News:Health News:WAT-AAH!, The First Functional Bottled Water For Kids, Announces The Release of WAT's-THE-WORD?! 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 3Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3Health News:Immune system activated in schizophrenia 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2
... is a threaded titanium anchor, ... procedures. The anchor features wide ... to optimize bone purchase, as ... to prevent suture binding. Fastin ...
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... 'proximal protection' -- providing complete protection from ... vessels with side branches. , ,Proxis ... does not require the attachment or exchange ... debris. ,Proxis is compatible with all ...
... System is the Fischer answer to cost ... specialist. The EP-X system is a highly ... dedicated EP lab system. Ease of access ... Pulsed Progressive Fluoroscopy (PPF) are but a ...
Medicine Products: